Mark Tyndall

21.2k total citations · 2 hit papers
263 papers, 16.2k citations indexed

About

Mark Tyndall is a scholar working on Epidemiology, Infectious Diseases and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Mark Tyndall has authored 263 papers receiving a total of 16.2k indexed citations (citations by other indexed papers that have themselves been cited), including 209 papers in Epidemiology, 120 papers in Infectious Diseases and 82 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Mark Tyndall's work include HIV, Drug Use, Sexual Risk (162 papers), HIV/AIDS Research and Interventions (111 papers) and Opioid Use Disorder Treatment (74 papers). Mark Tyndall is often cited by papers focused on HIV, Drug Use, Sexual Risk (162 papers), HIV/AIDS Research and Interventions (111 papers) and Opioid Use Disorder Treatment (74 papers). Mark Tyndall collaborates with scholars based in Canada, United States and Australia. Mark Tyndall's co-authors include Evan Wood, Thomas Kerr, Julio Montaner, Robert S. Hogg, Martin T. Schechter, Kate Shannon, Kathy Li, Michael V. O’Shaughnessy, Steffanie A. Strathdee and Jean Shoveller and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Mark Tyndall

257 papers receiving 15.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review

2008 1.0k citations Mark Tyndall et al. profile →
Opioid use disorder

2020 354 citations Mark Tyndall et al. profile →

Peers

Countries citing papers authored by Mark Tyndall

Since Specialization

Citations

This map shows the geographic impact of Mark Tyndall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Tyndall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Tyndall more than expected).

Fields of papers citing papers by Mark Tyndall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Tyndall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Tyndall. The network helps show where Mark Tyndall may publish in the future.

Co-authorship network of co-authors of Mark Tyndall

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Tyndall. A scholar is included among the top collaborators of Mark Tyndall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Tyndall. Mark Tyndall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	What is killing people with hepatitis C virus infection? Analysis of a population-based cohort in Canada 2019 ·International Journal of Drug Policy ·Mel Krajden, Darrel Cook, Stanley Wong, Amanda Yu, Zahid A Butt, Carmine Rossi, Maryam Darvishian, Maria Alvarez, Jane A. Buxton, Mark Tyndall, Naveed Z. Janjua	16
2	Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy 2019 ·Hepatology Communications ·Naveed Z. Janjua, Maryam Darvishian, Stanley Wong, Amanda Yu, Carmine Rossi, Alnoor Ramji, Eric M. Yoshida, Zahid A Butt, Hasina Samji, Mei Chong, N. Chapinal, Darrel Cook, Maria Alvarez, Mark Tyndall, Mel Krajden, (unknown)	22
3	Loss to follow‐up: A significant barrier in the treatment cascade with direct‐acting therapies 2019 ·Journal of Viral Hepatitis ·Maryam Darvishian, Stanley Wong, Mawuena Binka, Amanda Yu, Alnoor Ramji, Eric M. Yoshida, Jason Wong, Carmine Rossi, Zahid A Butt, Sofia Bartlett, Margo Pearce, Hasina Samji, Darrel Cook, Maria Alvarez, Mei Chong, Mark Tyndall, Mel Krajden, Naveed Z. Janjua	23
4	Applying core theory and spatial analysis to identify hepatitis C virus infection “core areas” in British Columbia, Canada 2018 ·Journal of Viral Hepatitis ·Zahid A Butt, Sunny Mak, Dionne Gesink, Mark Gilbert, Jason Wong, Amanda Yu, Stanley Wong, Maria Alvarez, Mei Chong, Jane A. Buxton, Mark Tyndall, Mel Krajden, Naveed Z. Janjua	3
5	Estimating the impact of early hepatitis C virus clearance on hepatocellular carcinoma risk 2018 ·Journal of Viral Hepatitis ·Maryam Darvishian, Naveed Z. Janjua, Mei Chong, Darrel Cook, Hasina Samji, Zahid A Butt, Amanda Yu, Maria Alvarez, Eric M. Yoshida, Alnoor Ramji, Jason Wong, Ryan Woods, Mark Tyndall, Mel Krajden	8
6	Management and Point-of-Care for Tobacco Dependence (PROMPT): a feasibility mixed methods community-based participatory action research project in Ottawa, Canada 2018 ·BMJ Open ·Smita Pakhalé, (unknown), (unknown), (unknown), (unknown), (unknown), Robert D. Boyd, (unknown), Gonzalo G. Alvarez, Mark Tyndall	11
7	Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study 2017 ·BMC Infectious Diseases ·(unknown), Valérie Martel‐Laferrière, Roy Nitulescu, Joseph Cox, Curtis Cooper, Mark Tyndall, Danielle Rouleau, Sharon Walmsley, (unknown), Marina B. Klein	6
8	A Comparison of Web and Telephone Responses From a National HIV and AIDS Survey 2016 ·JMIR Public Health and Surveillance ·(unknown), Liviana Calzavara, Dan Allman, Catherine Worthington, Mark Tyndall, James Iveniuk	22
9	Impact of drug use and opioid substitution therapy on hepatitis C reinfection: The BC Hepatitis Testers Cohort 2016 ·Hepatology ·Md. Nazrul Islam, Mel Krajden, Jean Shoveller, Paul Gustafson, Mark Gilbert, Jane A. Buxton, Jason Wong, Mark Tyndall, Naveed Z. Janjua	4
10	Assessing Hepatitis C Burden and Treatment Effectiveness through the British Columbia Hepatitis Testers Cohort (BC-HTC): Design and Characteristics of Linked and Unlinked Participants 2016 ·PLoS ONE ·Naveed Z. Janjua, Margot Kuo, Mei Chong, Amanda Yu, Maria Alvarez, Darrel Cook, (unknown), (unknown), Karen Li, (unknown), Ryan Woods, David Godfrey, Jason Wong, Mark Gilbert, Mark Tyndall, Mel Krajden	56
11	Individual and jurisdictional factors associated with voluntary HIV testing in Canada: Results of a national survey, 2011 2015 ·Canadian Journal of Public Health ·Catherine Worthington, Liviana Calzavara, (unknown), Dan Allman, Mark Tyndall	5
12	Crack across the Americas – A massive problem in continued search of viable answers: Exemplary views from the North (Canada) and the South (Brazil) 2013 ·International Journal of Drug Policy ·Benedikt Fischer, Marcelo Santos Cruz, Francisco Inácio Bastos, Mark Tyndall	32
13	Do Supervised Injecting Facilities Attract Higher-Risk Injection Drug Users? 2005 ·American Journal of Preventive Medicine ·Evan Wood, Mark Tyndall, Kathy Li, Elisa Lloyd‐Smith, Will Small, Julio Montaner, Thomas Kerr	104
14	Potential use of safer injecting facilities among injection drug users in Vancouver's Downtown Eastside. 2003 ·PubMed ·Thomas Kerr, Evan Wood, Dan Small, Anita Palepu, Mark Tyndall	88
15	Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. 2003 ·Europe PMC (PubMed Central) ·Evan Wood, Julio Montaner, Benita Yip, Mark Tyndall, Martin T. Schechter, Michael V. O’Shaughnessy, Robert S. Hogg	193
16	Drug supply and drug abuse. 2003 ·Canadian Medical Association Journal ·Evan Wood, Mark Tyndall, Martin T. Schechter	1
17	Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996 2002 ·AIDS ·Evan Wood, Julio Montaner, Keith Chan, Mark Tyndall, Martin T. Schechter, David R. Bangsberg, Michael V. O’Shaughnessy, Robert S. Hogg	120
18	Hospital utilization and costs in a cohort of injection drug users. 2001 ·PubMed ·Anita Palepu, Mark Tyndall, Hernando León, Jean Muller, Michael V. O’Shaughnessy, Martin T. Schechter, Aslam H. Anis	225
19	A Randomized, Double‐Blind, Placebo‐Controlled Trial of Single‐Dose Ciprofloxacin versus Erythromycin for the Treatment of Chancroid in Nairobi, Kenya 1999 ·The Journal of Infectious Diseases ·(unknown), Mark Tyndall, (unknown), (unknown), Shaheed Vally Omar, Kelly S. MacDonald, Jos Perriëns, (unknown), Francis A. Plummer, Allan Ronald, Stephen Moses	29
20	Single Dose Azithromycin for the Treatment of Chancroid 1994 ·Sexually Transmitted Diseases ·Mark Tyndall, E. Agoki, Francis A. Plummer, (unknown), J. Ndinya-Achola, Allan Ronald	32

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact